Publikationen (54) Publikationen, an denen Forscher/innen teilgenommen haben

2015

  1. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

    Biomaterials, Vol. 67, pp. 274-285

  2. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs

    American Journal of Medicine, Vol. 128, Núm. 1, pp. 90.e9-90.e15

  3. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity

    Journal of Thrombosis and Haemostasis, Vol. 13, Núm. 7, pp. 1274-1278

  4. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    Blood, Vol. 125, Núm. 5, pp. 775-783

  5. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354

  6. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 20, Núm. 5, pp. 490-500

  7. Chronic exposure to IFNα drives medullar lymphopoiesis towards t-cell differentiation in mice

    Haematologica, Vol. 100, Núm. 8, pp. 1014-1022

  8. Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality

    Blood, Vol. 126, Núm. 7, pp. 858-862

  9. Cryopreservation of microencapsulated murine mesenchymal stem cells genetically engineered to secrete erythropoietin

    International Journal of Pharmaceutics, Vol. 485, Núm. 1-2, pp. 15-24

  10. Defining and treating high-risk multiple myeloma

    Leukemia, Vol. 29, Núm. 11, pp. 2119-2125

  11. Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: From hit identification to an optimized lead

    Journal of Medicinal Chemistry, Vol. 58, Núm. 5, pp. 2465-2488

  12. Direct-acting oral anticoagulants: Pharmacology, indications, management, and future perspectives

    European Journal of Haematology, Vol. 95, Núm. 5, pp. 389-404

  13. Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[(3 R)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]- N -methylbenzamide) (CM-352), for the Prevention and Treatment of Hemorrhage

    Journal of Medicinal Chemistry, Vol. 58, Núm. 7, pp. 2941-2957

  14. Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS)

    Medicina Intensiva, Vol. 39, Núm. 8, pp. 483-504

  15. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 7, pp. 398-403

  16. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study

    Thrombosis Research, Vol. 136, Núm. 6, pp. 1145-1148

  17. Fondaparinux in the initial and long-term treatment of venous thromboembolism

    Thrombosis Research, Vol. 135, Núm. 2, pp. 311-317

  18. Foro de debate: Seguridad de las alternativas a la transfusión alogénica en el paciente quirúrgico y/o crítico

    Medicina Intensiva, Vol. 39, Núm. 9, pp. 552-562

  19. Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia

    FASEB Journal, Vol. 29, Núm. 3, pp. 960-972

  20. Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells

    Stem Cell Reports, Vol. 5, Núm. 6, pp. 1053-1066